AACR PREVIEW: Early look at new cancer therapies
This article was originally published in Scrip
The American Association of Cancer Research (AACR) Annual Meeting 2013 from 6 to 10 April in Washington, DC will not generate a lot of headlines for late-stage therapies on the brink of regulatory approvals, but it will deliver early-stage data for technology and mechanisms of action worth watching as they progress in the clinic.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.